ARLINGTON, Va., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Privia Health Group, Inc. (Nasdaq: PRVA) today announced that it expects to release financial results for its fourth quarter and full-year periods ended December 31, 2024 before market open on Thursday, February 27, 2025.
The press release is expected to be publicly disseminated by 7:00 am ET and will also be available on the Company’s Investor Relations website at ir.priviahealth.com. Privia Health management will host a conference call beginning at 8:00 am ET on the same day, Thursday, February 27, to discuss the results and management’s outlook for future financial and operational performance.
You can visit ir.priviahealth.com/news-and-events/events-and-presentations to listen to the call via live webcast. The webcast will be archived and available for replay for on-demand listening shortly after the completion of the call under the same link. To participate in the live conference call, dial 646-968-2525 (or 888-596-4144 for international callers) and provide Conference ID 5704885.
About Privia Health
Privia Health™ is a technology-driven, national physician enablement company that collaborates with medical groups, health plans, and health systems to optimize physician practices, improve patient experiences, and reward doctors for delivering high-value care in both in-person and virtual settings. The Privia Platform is led by top industry talent and exceptional physician leadership, and consists of scalable operations and end-to-end, cloud-based technology that reduces unnecessary healthcare costs, achieves better outcomes, and improves the health of patients and the well-being of providers. For more information, visit priviahealth.com.
Contact
Robert Borchert
SVP, Investor & Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
817.783.4841
Last Trade: | US$22.90 |
Daily Change: | -0.58 -2.47 |
Daily Volume: | 705,121 |
Market Cap: | US$2.750B |
November 07, 2024 October 29, 2024 August 08, 2024 |
Immix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREAmneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MOREEnd of content
No more pages to load